Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Setanaxib, When Administered With Pembrolizumab, in Patients With Recurrent or Metastatic SCCHN

Next Previous
X
Search
Trial Profile

A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Setanaxib, When Administered With Pembrolizumab, in Patients With Recurrent or Metastatic SCCHN

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Setanaxib (Primary) ; Pembrolizumab
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Calliditas Therapeutics

    • Most Recent Events

    • 21 Aug 2024 Planned End Date changed from 1 Sep 2024 to 1 Nov 2025.
    • 16 May 2024 According to a Callitas Therapeutics media release, company will host an in-person and virtual R&D day on Thursday, May 30, 2024 at 3:00 PM CET (9:00 AM ET). The event will be held at Inderes Event Studio, Vastra Tradgardsgatan 19, Stockholm to discuss positive clinical results of this study.
    • 06 May 2024 Results presented in the Calliditas Therapeutics Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top